Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169761 | 0.91 | TP53 (0.83) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL5922348 | 0.88 | LMNA (0.69) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7166012 | 0.87 | LMNA (0.66) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7165586 | 0.87 | TP53 (0.74) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7172634 | 0.86 | LMNA (0.67) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7173115 | 0.85 | LMNA (0.66) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7165532 | 0.85 | LMNA (0.66) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7167950 | 0.85 | MAPT (0.75) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7169456 | 0.83 | TP53 (0.71) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL12851588 | 0.82 | TP53 (0.63) | LMNATP53MAPTPOLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6569890-B2 | Antiinflamamtory agents | ICOS CORPORATION | 2003-05-27 | — | — | US | claimed |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-01-16 | — | — | US | claimed |
| EP-1244620-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2001047880-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| US-6569890-B2 | Antiinflamamtory agents | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1244620-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6372777-B1 | ENZYME INHIBITORS TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, AS WELL AS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, | ICOS CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001047880-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | LMNA 4631/4885TP53 4526/4885MAPT 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.